Each of four tested IDH1 and IDH2 mutations reduced the enzymatic activity of the encoded protein. Mutations of NADP+-dependent isocitrate dehydrogenases encoded by IDH1 and IDH2 occur in a majority of several types of malignant gliomas.doi:10.1056/NEJMoa0808710Emilie De Carli...
IDH mutations are oncogenic, although whether the mechanism is through alterations in hydroxylases, redox potential, cellular metabolism, or gene expression is not clear. The mutations also drive increased methylation in gliomas. Gliomas with mutated IDH1 and IDH2 have improved prognosis compared with ...
2. Yan, H. et al. IDH1 and IDH2 mutations in gliomas. The New England journal of medicine360, 765-773, doi:10.1056/NEJMoa0808710 (2009).3. Waitkus, M. S., Diplas, B. H. & Yan, H. Biological Role and Therapeutic Potential of IDH Mutations in Cancer. Cancer cell 34, 186-195...
2. Yan, H. et al. IDH1 and IDH2 mutations in gliomas.The New England journal of medicine360, 765-773, doi:10.1056/NEJMoa0808710 (2009). 3. Waitkus, M. S., Diplas, B. H. & Yan, H. Biological Role and Therapeutic Poten...
IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360: 765–773. 24 Bleeker FE, Lamba S, Leenstra S, Troost D, Hulsebos T, Vandertop WP et al. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat ...
[6]Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med.2009;360(8):765-773. [7][4] Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations ...
Mutations were also found in 40% of solitary central cartilaginous tumors and in four chondrosarcoma cell lines, which will enable functional studies to assess the role of IDH1 and IDH2 mutations in tumor formation.This is a preview of subscription content, access via your institution ...
Somatic mutations of isocitrate dehydrogenase 1 and 2 (IDH1/2) are strongly associated with pathological subtypes, genetic profiles, and clinical features in gliomas. TheIDH1/2status is currently regarded as one of the most important molecular markers in gliomas and should be assessed accurately and...
IDH1 and IDH2 mutations in gliomas. N Engl J Med, 360 (8) (2009), pp. 765-773 CrossrefView in ScopusGoogle Scholar 2 S Schnittger, C Haferlach, M Ulke, T Alpermann, W Kern, T Haferlach IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate...
4.Yan H, Parsons D W, Jin G, et al. IDH1 and IDH2 mutations in gliomas[J]. The New England Journal of Medicine, 2009, 360(8): 765-773. 5.Mardis E R, Ding L, Dooling D J, et al. Recurring mutation...